Navigation Links
Misonix Reports Financial Results for First Half of Fiscal 2013
Date:2/7/2013

ed to net income of $136,000, or $0.02 per share, which included a gain of $712,000 for the sale of the Company's Laboratory and Forensic Safety Products Business in the first half of 2012.
  • Cash and cash equivalents totaled $6.9 million at December 31, 2012 with no long-term debt.
  • Increased the number of independent representatives from 19 to 42 in neurospine for the three months ended December 31, 2012.
  • Increased the number of independent representatives for wound care from 5 to 15 for the three months ended December 31, 2012.
  • Terminated the non-exclusive Aesculap Agreement as of December 31, 2012, which among other things should result in increased direct sales to customers at a higher margin.
  • Q2 2013 Financial Results:

    For the second quarter of fiscal 2013, revenue was $3.5 million, comparable to $3.6 million in the second quarter of 2012. BoneScalpel revenues for the quarter increased 33% to $1.6 million compared to $1.2 million in the comparable quarter of fiscal 2012. BoneScalpel units sold/placed for the quarter were 33. SonicOne revenues increased 70% to $528,249 compared to $309,812 in the second quarter last year. SonicOne units sold/placed for the quarter were 16. SonaStar revenues decreased 20% to $1.1 million compared to $1.3 in the second quarter last year. SonaStar units sold/placed for the quarter were 13. The number of BoneScalpel consumables sold increased 119% to 9,041 units for the quarter, SonicOne consumables sold increased 24% to 3,302 units, and SonaStar consumables sold decreased 40% to 1,985 units.

    As expected, other revenue, which includes legacy products Autosonix and Lysonix sold by outside distribution partners, decreased 59% as these late stage products approach end-of-life. Excluding all other revenue, BoneScalpel, SonicOne and SonaStar revenue increased 12% for the three months ended December 31, 2012.

    For the quarter, royalty income received predominantly from Cov
    '/>"/>

    SOURCE Misonix, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Misonix Presents at MicroCapClub Invitational
    2. Misonix Terminates Distribution Agreement With Aesculap
    3. Misonix Reports Strong Revenue Increases for the First Quarter of Fiscal 2013
    4. Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012
    5. Misonix Product Featured At Neurosurgery Congress
    6. Misonix Adds 6 Spine Sales Agencies In The U.S.
    7. Misonix Attends International Meeting On Advanced Spine Techniques (IMAST) - Introduces New Product
    8. Misonix Inks New Distribution Agreement For Croatia And Slovenia
    9. Misonix And Soelim Create New Distribution Alliance For South Korea
    10. Misonix Participates In Cleveland Spine Review
    11. Misonix Adds Industry Veteran To Management Team
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
    (Date:11/26/2014)... 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, ... Dr. Helen Torley , President and Chief Executive ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
    (Date:11/24/2014)... Juno Therapeutics today announced that the ... company,s JCAR015 chimeric antigen receptor product candidate.  The ... refractory B-cell acute lymphoblastic leukemia and was filed ... Center, where Phase 1 clinical trials are currently ... important news for patients who may benefit from ...
    Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
    (Date:11/26/2014)... (PRWEB) November 26, 2014 Anthropologists ... effectiveness in containing and stopping Ebola, improve international ... in healthcare systems in West Africa. , ... to Stop Ebola: Anthropologists Offer Insights,” will be ... the American Anthropological Association (AAA), Fri., Dec. 5, ...
    (Date:11/26/2014)... San Luis Obispo, CA (PRWEB) November 26, 2014 ... bunion treatment, is offering lower prices in an early ... November 26th, Bunion Booties are being offered at the ... Black Friday promotional pricing is in addition to any ... Bootie, visit the Bunion Bootie website for ...
    (Date:11/26/2014)... News Facts , Lexmark’s ... RSNA 2014 in Chicago. The company will demonstrate ... images, photos, videos and documents found throughout the ... learn more about these innovative medical content management ... initiatives – that enable more informed clinical decisions, ...
    (Date:11/26/2014)... who enter puberty early are at increased risk for ... linked with a number of factors associated with depression, ... to the researchers. Early puberty was also linked to ... and having friends who were prone to getting into ... an association between early puberty and these factors, it,s ...
    (Date:11/26/2014)... The number of emergency department visits in the United States ... 136 million in 2011, according to the U.S. Centers for ... fewer people were going to ERs with non-urgent medical needs: ... within two hours of arriving at the ER. In 2010, ... Sixty percent of patients arrived at the ER after normal ...
    Breaking Medicine News(10 mins):Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:ER Visits on the Rise, Study Reports 2
    ... Neurological Disease have now proved using a specialized mouse ... produced by neurons.// The results of this study have ... the two. ,Also known as apoE, this ... apoE4, is the major known genetic risk factor for ...
    ... Foundation has found that more than 60 percent of people ... food debris// struck in between their teeth. Items like screwdrivers, ... survey said. ,More disturbingly, the survey said that ... rise to oral health problems and bad breath. "Clearly people ...
    ... is running short of faculty members and its current strength ... ,Replying to a question, minister of state for health ... running with just 479 faculty members as against its sanctioned ... that during 2003-05, 20 faculty members had either resigned or ...
    ... and Medicaid Services in Baltimore and George Washington University ... who are depressed resort to nursing homes. Depression among ... of the patient. Hence the researchers analyzed the relationship ... surveyed a total of 141,000 seniors. About 13261 of ...
    ... Although the new government health refoms have cost millions of pounds ... very little benefit for the patients//. ,Cosultants pay and pension ... state that there is no difference to patient care. ... the hospitals. There has been no planning and no guidance on ...
    ... but still South Africa's own nursing community is faced ... salute the nurses of South Africa and celebrate those ... lives of others in need," said Siphokazi Phillip, international ... Africa (Denosa). ,According to Philip although there ...
    Cached Medicine News:Health News:Alzheimer's-linked apolipoprotein E produced by neurons, Gladstone study 2Health News:Nurses in South Africa Face Challenges 2
    Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
    Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
    For the quantitative determination of alanine aminotransferase in serum used in routine examination and monitoring of therapy and relapses....
    For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
    Medicine Products: